Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on

Related Experiment Videos

F Peters-Klimm1, T Müller-Tasch, D Schellberg

  • 1Department of General Practice and Health Services Research, University Hospital Heidelberg, Vossstrasse 2, Heidelberg 69115, Germany. frank.peters@med.uni-heidelberg.de

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|November 30, 2007
PubMed

Insights

General practitioners (GPs) showed good guideline adherence (GA) for chronic heart failure (CHF) pharmacotherapy using standard criteria. However, optimizing drug dosages revealed significant room for improvement in CHF treatment.

Area of Science:

  • Cardiology
  • Primary Care Medicine
  • Pharmacotherapy

Background:

  • Evidence supports pharmacotherapy for chronic heart failure (CHF), leading to treatment guidelines.
  • Surveys indicate under-utilization of recommended CHF drugs.
  • Treatment patterns are influenced by clinical setting and patient demographics.

Purpose of the Study:

  • To evaluate guideline adherence (GA) of general practitioners (GPs) for CHF patients in primary care.
  • Assess GA based on drug prescription, target dosing, and contraindications.

Main Methods:

  • Cross-sectional analysis of 167 patients with left ventricular systolic dysfunction (LVEF: 33.3 ± 6.9%) across 37 GP practices in Germany.
  • GA assessed via prescription rates, target dose achievement, and a modified Guideline Adherence Indicator-3 (mGAI-3).
  • mGAI-3 evaluated adherence to ACE-Inhibitors (ACE-I)/angiotensin receptor blockers (ARB), beta-blockers (BB), and aldosterone-antagonists (AA) based on NYHA functional class.

Main Results:

  • Prescription rates: ACE-I/ARB (80%), BB (75%), both (62%).
  • Proportion of target doses reached: ACE-I (16%), BB (8%).
  • Adjusted for contraindications, target doses increased: ACE-I/ARB (49%), BB (46%). mGAI-3 showed moderate to perfect GA in 83% (usual), 16% (target dose), and 55% (adjusted).

Conclusions:

  • Life-saving CHF pharmacotherapy was provided above average based on usual assessment criteria in this setting.
  • Utilizing additional criteria, such as target dosing and contraindication adjustments, highlights areas for treatment optimization.
  • Future interventions should be tailored to the specific needs of both doctors and patients to improve CHF management.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...